Biogen CEO: We need to be the 'Tesla' of drug pricing model

In an exclusive CNBC interview Michel Vounatsos, Biogen CEO talks to CNBC's Meg Tirrell at the J.P. Morgan Health Care Conference about investing in health care under President Trump and the impact of tax reform on mergers and acquisition. Also Vounatsos weighs in on Biogen's drug pipeline and drug pricing.
Mon, Jan 8 20188:35 AM EST